HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results GlobeNewswire September 02, 2025 Highlights of the second quarter include: Revenue of $325.8 million, an increase of 9% compared to $299.9 million in Q2 FY25. Net income of $59.9 million, an increase of 67% compared to $35.8 million in Q2 FY25, with non-GAAP net income […]
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference GlobeNewswire September 02, 2025 WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will
(NASDAQ:CGTX), PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately
(NASDAQ:WATFX),(NASDAQ:WABAX),(NASDAQ:WABCX),(NASDAQ:WAPIX),(NASDAQ:WACSX),(NASDAQ:WABRX),(NASDAQ:WAPAX),(NASDAQ:WAPCX),(NASDAQ:LWCPX),(NASDAQ:WACIX),(NASDAQ:WAPRX),(NASDAQ:WACPX),(NASDAQ:WAPSX), NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Western Asset Management Company, LLC (“WAMCO” or the “Company”), Franklin Resources, Inc. (“Franklin”), and Stephen Kenneth Leech, II (“Leech”) (collectively, “Defendants”). Class Definition This lawsuit
(NYSE:SLQT), NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SelectQuote, Inc. (“SelectQuote” or “the Company”) (NYSE: SLQT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against
(NASDAQ:TSLA), NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tesla, Inc. (“Tesla” or “the Company”) (NASDAQ: TSLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against
Session will be Webcast Martina Cheung, President and Chief Executive Officer of S&P Global (NYSE: SPGI), will participate in Barclays 23rd Annual Global Financial Services Conference on September 9, 2025 in New York, New York. Ms. Cheung is scheduled to speak from 12:00 p.m. to 12:40 p.m. (Eastern Daylight Time). The “fireside chat” will be
Crescent Electric Supply Company, one of the nation's largest independent distributors of electrical hardware and supplies, today announced that Penny Cotner has been appointed President and Chief Executive Officer, effective October 1, 2025. https://mma.prnewswire.com/media/2762596/Crescent_Electric_Supply_Company_CEO_Penny_Cotner.jpg Cotner joins Crescent after a 12-year tenure at Infinite Electronics, a global supplier of electronic components, including the past seven years
Heismeyer to lead with discipline, collaboration, and strategic focus Landus, Iowa's largest farmer-owned cooperative, announced today that Eric Heismeyer will join the organization as Chief Executive Officer, effective September 3, 2025. His appointment reaffirms Landus and the Board of Directors' commitment to finding a forward-thinking, proven leader who understands the key role cooperatives play in
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) GlobeNewswire September 02, 2025 PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that